MORPHINE SULFATE (morphine sulfate) by Fresenius Kabi is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2013.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
Morphine Sulfate is a full mu-opioid receptor agonist indicated for acute pain management via intramuscular or intravenous injection. It works by binding to opioid receptors in the central nervous system to produce analgesia without a ceiling effect on pain relief. The precise mechanism involves modulation of endogenous opioid pathways throughout the brain and spinal cord.
Peak lifecycle stage with 7.7 years of patent protection remaining suggests stable commercial operations with a mature portfolio team.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Morphine Sulfate offers stability in a mature, regulated product but limited growth opportunities given the peak lifecycle stage and absence of clinical expansion programs. Career development may focus on operational excellence, supply chain resilience, and margin protection rather than innovation or market expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo